RxDoctor Payments Data

John O'Laughlin, MD

Critical Care Medicine · Albany, NYNPI 1356761894

Payments from drug & device makers

$3,682in general payments, 2019–2025

Across 145 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$687
  • Boehringer Ingelheim$586
  • Cardiovascular Systems Inc.$318
  • Novartis$317
  • Abbott$277
  • Edwards Lifesciences$272
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,682 in reported general payments places this provider in the 85th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$412,902
Medicare patients
1,618
Services billed
3,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban262$303,155
EntrestoSacubitril/Valsartan90$111,602
BrilintaTicagrelor145$86,329
XareltoRivaroxaban75$73,751
JardianceEmpagliflozin37$38,238
Repatha SyringeEvolocumab17$15,724
Ranolazine ErRanolazine49$7,977
Metoprolol Succinate373$6,529
Praluent PenAlirocumab13$6,162
Atorvastatin Calcium241$3,475
Rosuvastatin Calcium220$2,556
Ezetimibe51$2,436
Amiodarone Hcl18$2,235
Losartan Potassium172$1,768
Amlodipine Besylate301$1,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$131$303,155262 claims
NovartisEntresto$317$111,60290 claims
AstraZenecaBrilinta$68$86,329145 claims
Johnson & JohnsonXarelto$204$73,75175 claims
Boehringer IngelheimJardiance$586$38,23837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →